Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 10
1966 29
1967 47
1968 82
1969 151
1970 177
1971 169
1972 123
1973 114
1974 114
1975 106
1976 97
1977 71
1978 82
1979 74
1980 79
1981 108
1982 85
1983 74
1984 90
1985 81
1986 75
1987 114
1988 148
1989 189
1990 171
1991 175
1992 197
1993 245
1994 271
1995 497
1996 976
1997 924
1998 1229
1999 1009
2000 1066
2001 1217
2002 1174
2003 1305
2004 1416
2005 1603
2006 1556
2007 1584
2008 1738
2009 1789
2010 1792
2011 1891
2012 1930
2013 2072
2014 2129
2015 2023
2016 1883
2017 1698
2018 1620
2019 793
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

37,300 results
Results by year
Filters applied: . Clear all
Page 1
Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs
Lebrun C and Rocher F. CNS Drugs 2018 - Review. PMID 30143945
Since 2000, more than 15 immunosuppressant (IS) drugs have been used, with a more or less specific action on inflammation. These include monoclonal antibodies targeting CTL4, the integrin receptor, the interleukin (IL)-2 receptor, CD19, CD20, CD52, and the sphingosine 1 phosphate family. ...We review the current evidence behind the increased risk of malignancy in MS patients receiving DMTs, and provide an overview of the DMTs that are currently in use and those in clinical trials. ...
Since 2000, more than 15 immunosuppressant (IS) drugs have been used, with a more or less specific action on inflammation. These incl …
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M, et al. Ther Drug Monit 2019 - Review. PMID 31045868
In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. ...In addition, monitoring intracellular T-cell IFN-g production can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II). ...
In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and …
Current trends in immunosuppressive treatment.
Sobotková M and Bartůňková J. Vnitr Lek 2019 - Review. PMID 30909704
Immunosuppressive agents represent a class of drugs that inhibits activity of the immune system. They are mostly used in autoimmune diseases and other inflammatory conditions treatment and in prevention of recipient´s immune response to donors antigens in transplantations. There is a broad spectrum of different immunosuppressive drugs with various mechanisms of action. This article provides an overview of drugs currently registered as immunosuppressive agents in the Czech Republic and provides some insights what we might expect regarding this group of drugs in the future....
Immunosuppressive agents represent a class of drugs that inhibits activity of the immune system. They are mostly used in autoi
Novel immunosuppressants.
Krieger NR and Emre S. Pediatr Transplant 2004 - Review. PMID 15598332
This review will outline a number of immunosuppressive agents that are currently being explored in experimental and clinical transplantation. These include biologic agents that have more specificity and selectivity, and are aimed at T-cell depletion, blockade of costimulation, adhesion markers, or at novel targets. ...
This review will outline a number of immunosuppressive agents that are currently being explored in experimental and clinical t …
[Immunosuppressive treatment and bone healing].
Horn D, et al. Unfallchirurg 2019 - Review. PMID 31190108 German.
Due to demographic changes in the population and the development of novel immunosuppressive agents, an increasing number of trauma and orthopedic patients are taking concomitant immunosuppressive medication. ...In these complex situations a structured and interdisciplinary process during hospital admission should preoperatively evaluate the possibility of interrupting immunosuppressive medications for the perioperative treatment period without risking a relapse of the underlying disease and which surgical approach should be individually selected for the patient....
Due to demographic changes in the population and the development of novel immunosuppressive agents, an increasing number of tr …
Immunosuppressive drugs after solid organ transplantation.
van Sandwijk MS, et al. Neth J Med 2013 - Review. PMID 23956308 Free article.
In recent years solid organ transplantation has been rapidly developed as a therapeutic intervention that is life-saving and greatly contributes to a better quality of life in organ recipients. ...In this review manuscript we will discuss current and future immunosuppressive strategies that are employed in solid organ transplantation. ...
In recent years solid organ transplantation has been rapidly developed as a therapeutic intervention that is life-saving and greatly …
Immunosuppressive drug therapy.
Hartono C, et al. Cold Spring Harb Perspect Med 2013 - Review. PMID 24003247 Free PMC article.
The first successful kidney transplantation between monozygotic identical twins did not require any immunosuppressive drugs. ...Progress in our understanding of the immunobiology of rejection has been translated to the development of immunosuppressive agents targeting T cells, B cells, plasma cells, costimulatory signals, complement products, and antidonor antibodies. ...
The first successful kidney transplantation between monozygotic identical twins did not require any immunosuppressive drugs. ...Progr …
Immunosuppressive agents and interstitial lung disease: what are the risks?
Meyer KC. Expert Rev Respir Med 2014. PMID 24649876
In contrast, some forms of interstitial lung disease can respond well to treatment with immunosuppressive drug therapies. Such agents can, however, be associated with significant risk of adverse effects such as infection, diabetes, osteoporosis, myopathy, bone marrow suppression, hepatitis, urinary tract injury, and drug-induced pneumonitis. ...Some disorders (e.g., cellular non-specific interstitial pneumonia, organizing pneumonia, or sarcoidosis) may respond very well to immunosuppressive therapies including corticosteroids as monotherapy, and the use of steroid-sparing agents can minimize corticosteroid side effects and may enhance treatment efficacy for disorders such as sarcoidosis or connective tissue disease-associated forms of interstitial lung disease....
In contrast, some forms of interstitial lung disease can respond well to treatment with immunosuppressive drug therapies. Such age
Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease.
Østensen M, et al. J Rheumatol 2007. PMID 17516615
Ninety-four women and 47 men had received one or several immunosuppressive or biological agents during the years 2000-2005. Correct advice in regard to drugs and necessary birth control had been given to 84% of women. ...The increasing use of combination therapies containing MTX necessitates ensuring that advice regarding birth control is followed in order to avoid pregnancies exposed to potentially fetotoxic drugs....
Ninety-four women and 47 men had received one or several immunosuppressive or biological agents during the years 2000-2005. Co …
37,300 results
Jump to page
Feedback